Market Overview

Piper Jaffray Starts CymaBay At Overweight With $4 Target, Discusses MBX-8025


In a report published Tuesday, Piper Jaffray analyst Edward A. Tenthoff initiated coverage of CymaBay Therapeutics Inc (NASDAQ: CBAY) with an Overweight rating and a price target of $4, after news that the company had raised cash to advance MBX-8025.

CymaBay issued 7.1 million shares at $2.81 per share, taking the estimated pro forma cash to $51 million, or $2.10 per share. CymaBay plans to invest this capital to advance MBX-8025 in Homozygous Familial Hypercholesterolemia (HoFH), data from which is expected in 4Q15, as well as initiate a Phase II trial in Primary Biliary Cirrhosis (PBC).

"In a Phase II trial in mixed dyslipidemia patients, MBX-8025 significantly reduced LDLc and markers of liver inflammation. Now CymaBay is focusing development of MBX-8025 in rare conditions with unmet need, potentially accelerating the path to market," analyst Edward Tenthoff wrote.

CymaBay is conducting a Phase II study in HoFH and, based on positive results, the company may initiate pivotal Phase II trials in 2016 and reach the market in 2020.

CymaBay is to begin a 12-week Phase II study of MBX-8025 in 4Q15. Tenthoff expects data in 4Q16 and a US launch in 2021.

"Arhalofenate completed a Phase IIb trial in gout earlier this year. Despite mixed results, we see an opportunity for arhalofenate to be used in combination therapy. CymaBay intends to partner arhalofenate prior to initiating Phase III trials," the Piper Jaffray report stated.

Latest Ratings for CBAY

Feb 2019B. Riley FBRInitiates Coverage OnNeutral
Jun 2018Raymond JamesInitiates Coverage OnOutperform
Feb 2018Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for CBAY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Analyst Ratings


Related Articles (CBAY)

View Comments and Join the Discussion!

Latest Ratings

VREXNorthland SecuritiesInitiates Coverage On42.0
EAMorgan StanleyMaintains88.0
ELMorgan StanleyMaintains178.0
SPLKMorgan StanleyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

IBM Transformation Continues, Cantor's Brian White Reiterates Buy

Mid-Morning Market Update: Markets Mostly Lower; Verizon Q2 Profit Tops Views